Market Place
Sourcing Support
Gannex Presents Positive ASC41 Phase 2 MASH Data At EASL 2024
10 Jun 2024 //
PR NEWSWIRE
Gannex Announces Positive Results from Phase II Trial of Once-Daily ASC41 Tablet
02 Jan 2024 //
PR NEWSWIRE
Ascletis’ Gannex reports positive interim PhII NASH data
02 Jan 2024 //
ENDPTS
Gannex posts data on NASH asset at center of trade secret row
02 Jan 2024 //
FIERCE BIOTECH
Gannex Published Phase I Data of ASC42
05 Nov 2023 //
PR NEWSWIRE
Gannex Announces the Completion of Patient Enrollment for PII Trial of ASC42
19 Jul 2023 //
PR NEWSWIRE
NAFLD clinical trial activity catching up in Chin, lacks domestic participation
27 Dec 2022 //
INDIANPHARMAPOST
Gannex doses first participant in primary biliary cholangitis DDI study
16 Aug 2022 //
CLINICALTRIALSARENA
Gannex Begins Dosing in the U.S. Drug-Drug Interaction Study of ASC42
15 Aug 2022 //
PRNEWSWIRE
Gannex Begins Dosing in Phase II Trial of ASC42 for Primary Biliary Cholangitis
10 Apr 2022 //
PRNEWSWIRE
Gannex Announces Completion of the U.S. Phase I Trial of ASC43F for NASH
04 Jan 2022 //
ASIAONE
First Subject Dosed in U.S. Phase I Trial for ASC43F
17 Nov 2021 //
PRNEWSWIRE
Gannex gets China NMPA nod for phase II and III protocols of ASC42
16 Nov 2021 //
PHARMABIZ
Gannex Announces U.S. IND Approval of ASC43F, a First-in-Class Dual-Target
01 Nov 2021 //
PRNEWSWIRE
Gannex Announces Clinical and Preclinical Data of Four NASH Programs
13 Oct 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.